Logo

argenx and Zai Lab Report the NMPA’s Approval of Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

Share this
Zai Lab & argenx

argenx and Zai Lab Report the NMPA’s Approval of Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

Shots:

  • The NMPA has granted approval to the sBLA of Vyvgart Hytrulo [1,000mg (5.6ml)/vial], a once-weekly SC injection, for treating adults with chronic inflammatory demyelinating polyneuropathy (CIDP)
  • Approval was based on the results from ADHERE trial for CIDP. Zai Lab recruited participants in Greater China and observed responses similar to trial outcomes carried out worldwide
  • Study showed a reduction of 69% in relapse risk among Chinese patients, with clinical improvement in 78% of them, indicating the role of IgG autoantibodies in the disease. Safety and tolerability aligned with global trial results

Ref: argenx | Image: Zai Lab & argenx

Related News:- Zai Lab and argenx Report the NMPA’s Approval of Efgartigimod Alfa SC Injection to Treat Generalized Myasthenia Gravis

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions